Eli Lilly Just Paid $3.8 Billion to Bet That Depression's Next Blockbuster Looks Like DMT

Eli Lilly — a company whose name is synonymous with insulin and Prozac, not Schedule I compounds — announced on July 16 that it will acquire AtaiBeckley for up to $3.8 billion: $2.8 billion up front, another $1 billion tied to milestones. The target is BPL-003, a fast-acting nasal spray built on mebufotenin, a DMT-based compound, now in Phase 3 trials for treatment-resistant depression, with pivotal data expected in early 2029.

Big Pharma isn’t waiting for psychedelic medicine to finish proving itself. It’s buying the proof in progress, at a price that makes clear it expects to win.

This is the largest deal the psychedelic-medicine sector has seen — and it’s the second nine-figure-plus acquisition in under a year, following AbbVie’s up-to-$1.2 billion purchase of Gilgamesh Pharmaceuticals’ lead candidate bretisilocin in 2025. AtaiBeckley itself is barely a year old, formed in late 2025 when Atai Life Sciences acquired Beckley Psytech; its pipeline also includes MDMA- and DMT-class programs beyond BPL-003. Lilly has said publicly it plans to spend more than $10 billion up front — potentially $25 billion total — across eight acquisitions this year. A DMT nasal spray for depression is now one of those eight bets.

The timing isn’t incidental. Lilly signed this deal two days after the FDA finalized its guidance on psychedelic clinical trials — the document written specifically to fix the “functional unblinding” problem that helped sink Lykos Therapeutics’ MDMA-assisted PTSD therapy in 2024, when regulators couldn’t trust a trial’s placebo arm because participants could tell within minutes whether they’d gotten the real drug. The new guidance pushes active-placebo designs, blinding questionnaires, and expectancy controls — a regulatory roadmap serious enough that a company with Lilly’s risk tolerance for FDA process was willing to write a $2.8 billion check against it.

None of this means treatment-resistant depression patients get a DMT nasal spray anytime soon; 2029 pivotal data is a long runway, and Schedule I status for the underlying compound class isn’t resolved by an acquisition. What it does mean is that the era of psychedelic medicine being a boutique, VC-funded, single-molecule bet is ending. When the company that makes Prozac decides DMT is a safer investment than sitting out the category, the story stops being about whether psychedelics work in a lab and starts being about who controls access once they do — and a $3.8 billion acquisition is a pretty clear vote for who Lilly thinks that will be.